Silverback Therapeutics Reaches Analyst Target Price
January 27, 2021 at 08:23 AM EST
In recent trading, shares of Silverback Therapeutics Inc (SBTX) have crossed above the average analyst 12-month target price of $47.33, changing hands for $47.60/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..